A Near-Infrared-II Antibody-Photosensitizer Conjugate for Photoimmunotherapy of Advanced Pancreatic Cancer
ACS Nano · 2026
DOI: 10.1021/acsnano.6c11768 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Nano, 2026. Verfasst von Dingyuan Yan und 7 weiteren Autor:innen. Beteiligte Einrichtung: Center for AIE Research, Guangdong Provincial Key Laboratory of New Energy Materials Service Safety, College of Materials Science and Engineering, Sh…. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Photosensitizing Agents, Immunotherapy, Immunoconjugates. Die Arbeit nennt 39 Literaturangaben. Gefördert von: Shenzhen University, Shenzhen Science and Technology Innovation Commission, National Basic Research Program of China (973 Program).
Abstract (Originalsprache)
Pancreatic cancer (PC) is a highly lethal malignancy, characterized by frequent late-stage diagnosis and limited response to available treatments. Photoimmunotherapy, which combines the localized tumor ablation of phototherapy with the systemic immune activation of immunotherapy, presents a promising strategy. However, its success is often hampered by insufficient accumulation of therapeutic agents at the tumor site. To address this challenge, we developed a novel antibody-photosensitizer conjugate, named αPD-L1@AIE, by conjugating a multifunctional phototheranostic agent with αPD-L1 antibody for targeted photoimmunotherapy of PC. The incorporation of αPD-L1 not only facilitates tumor-specific targeting but also acts as an immune checkpoint inhibitor. Upon 660 nm laser irradiation, this phototheranostic agent enables NIR-II fluorescence imaging and simultaneously induces potent immunogenic cell death (ICD) via combined photodynamic and photothermal therapy. Following localized phototherapy, the released tumor-associated antigens from ICD initiate a robust antitumor immune response. Such a response is synergistically amplified by αPD-L1, which together alleviates immunosuppression via Treg cell depletion and M2-like macrophage repolarization, thereby promoting a marked increase in cytotoxic T lymphocyte infiltration and granzyme B production. Consequently, the aforementioned photoimmunotherapy approach effectively suppresses tumor growth and inhibits spontaneous metastasis, demonstrating a powerful and transformative paradigm for advanced PC management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for AIE Research, Guangdong Provincial Key Laboratory of New Energy Materials Service Safety, College of Materials Science and Engineering, Shenzhen University, Shenzhen518060, China.
- State Key Laboratory of Digital Medical Engineering, School of Biomedical Engineering, Hainan University, Sanya572025, China.
- Key Laboratory of Biomedical Engineering of Hainan Province, One Health Institute, Hainan University, Sanya572025, China.
- Guangdong Basic Research Center of Excellence for Aggregate Science, School of Science and Engineering, The Chinese University of Hong Kong (Shenzhen), Longgang, Shenzhen, Guangdong518172, China.
ORCID-Profile: Feifan Zhou, Dong Wang, Ben Zhong Tang
Förderung
- Shenzhen University
- Shenzhen Science and Technology Innovation Commission
- National Basic Research Program of China (973 Program)
- National Natural Science Foundation of China (NSFC)
- Shenzhen Medical Research Fund
- Shenzhen Medical Academy of Research and Translation
Zitieren
APA
Yan, D., Wu, J., Tong, Y., Sheng, Z., Lin, D., Zhou, F., Wang, D., & Tang, B. Z. (2026). A Near-Infrared-II Antibody-Photosensitizer Conjugate for Photoimmunotherapy of Advanced Pancreatic Cancer. ACS Nano. https://doi.org/10.1021/acsnano.6c11768
Vancouver
Yan D, Wu J, Tong Y, Sheng Z, Lin D, Zhou F, et al. A Near-Infrared-II Antibody-Photosensitizer Conjugate for Photoimmunotherapy of Advanced Pancreatic Cancer. ACS Nano. 2026. doi:10.1021/acsnano.6c11768
BibTeX
@article{Yan2026,
author = {Yan, Dingyuan and Wu, Jinxian and Tong, Ye and Sheng, Zhijia and Lin, Danmin and Zhou, Feifan and Wang, Dong and Tang, Ben Zhong},
title = {A Near-Infrared-II Antibody-Photosensitizer Conjugate for Photoimmunotherapy of Advanced Pancreatic Cancer},
journal = {ACS Nano},
year = {2026},
doi = {10.1021/acsnano.6c11768}
}
EUVIMED